Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

A legfontosabb adatok

Ki végzi
Loyola University
Hol
Maywood (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
3 fő vett részt
Kezdés
2017. dec. 20.
Befejezés
2024. júl. 26.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • HDR Brachytherapy + EBRT + STAD
A regiszteradat frissítve
2026. január 29.
Miért állt le
The study was stopped for feasibility

Ki vehet részt

Életkor
18 év – 99 év
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Biopsy proven locally recurrent adenocarcinoma of the prostate after the completion of definitive radiation therapy for initially diagnosed prostate cancer
  • Initial cancer diagnosis that fits these specific criteria:; Stages cT1-T3a; Nx or N0; Mx or M0
  • Eligible initial definitive radiotherapy modalities include:; External beam radiotherapy, with photon or proton beam therapy; Definitive Brachytherapy; Stereotactic Body Radiotherapy
  • Fluciclovine-positive pelvic nodes (as determined by an interpreting radiologist or nuclear medicine physician) in the pelvic nodal region (defined as the pelvic nodal regions up to the common iliac nodal region) without any evidence of lymph node involvement outside of this area or distant metastases
  • Candidate for hormonal therapy
  • Current ECOG Performance status Scale 0-2 (Appendix D)
  • Current International Prostate Symptom Score (IPSS) < 20 (Appendix B)
  • Age >18
  • The patient must be medically suitable to receive general or spinal anesthesia
  • AST, ALT, and alkaline phosphatase < 2 x upper institutional limit within 3 months of registration
  • The patient must be able and willing to sign a study-specific written informed consent form before study entry

Ki nem vehet részt

  • Preregistration radiation-related GI or GU toxicity (for any reason) grade ≥ 3 as defined in CTCAE version 4.03. That is, grade ≥ 3 GU or GI toxicity after first course of radiotherapy
  • Treatment to a "whole pelvis" field with initial radiotherapy
  • Patients receiving any other investigational agents
  • Patients who have received chemotherapy or immunotherapy within one month prior to study enrollment, other than ADT
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, severely symptomatic congestive heart failure, cardiac arrhythmia, recent myocardial infarction in last 6 months, or psychiatric illness/social situations that could limit compliance with study requirements
  • Patients with distant metastases (such as to the bone, visceral organs, and lymph nodes other than the pelvic nodes including the common iliac nodes)

Helyszínek itt: Egyesült Államok

  • Loyola University Medical CenterMaywood, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate the safety and effectiveness of combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) to the pelvis and 6 months of hormonal therapy, otherwise known as short term androgen deprivation therapy (STAD), as treatment for prostate cancer that has come back in the prostate and pelvic lymph nodes after prior radiotherapy. The study will examine the side effects of the treatment as well as the ability of the treatment to get rid of the cancer. This involves the placement of a radioactive material in the affected area of the prostate temporarily, and then is subsequently removed using a minimally invasive technique. Participants will also receive external radiation for 5 weeks targeting the pelvis and giving a higher dose each day to the suspicious lymph nodes on PET scan. Radiation therapy will start approximately 2 months after the start of the Androgen Deprivation Therapy (hormone therapy). The hormone therapy consists of two medications, an oral medication taken daily 2 months before starting radiation therapy until the last of the radiation therapy and an injection of a medication which is given 2 months prior to the start of radiation. Patient are then followed at specific time intervals to evaluate the treatment side effects and cancer control

A vizsgálat csoportja

  • HDR Brachytherapy + EBRT + STADA vizsgált kezelés

    Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV. EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions. 6 months hormonal therapy(LHRH agonist and antiandrogen \[until the end of radiotherapy\])

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase I/II Study of Salvage High-dose-rate Brachytherapy, ExternAl Beam COmbined and Short-term Hormonal Therapy for the Treatment of Node-positive Locally Recurrent Prostate Cancer After Prior Definitive Radiotherapy
A regiszteradat frissítve
2026. január 29.